Genmab Licenses Synaffix’s Antibody-Drug Conjugate Technologies
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 1 (Table of Contents)
Published: 10 Jan-2022
DOI: 10.3833/pdr.v2022.i1.2654 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Continuing its interest in antibody-drug conjugate (ADC) therapies, Genmab has agreed to pay US$4...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS